RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") announced that it has received Orphan Drug designation from U.S. FDA's Office of Orphan Products Development (OOPD) for its drug candidate, Thymosin beta 4 ...
Tags: RegeneRx Biopharmaceuticals, Orphan Drug designation, Thymosin beta 4
RegeneRx Biopharmaceuticals has received an issued patent in Mexico and allowances of three additional patent applications in Mexico and Israel, related to Thymosin beta 4 (Tβ4). The patents are set to expire 2024-2026, the ...